Malondialdehyde antibody (Atto 390)

Catalog No. ABIN5067362

Product Details anti-Malondialdehyde Antibody (Atto 390)

Target: Malondialdehyde (MDA)

Reactivity: Please inquire

Host: Mouse

Clonality: Monoclonal

Conjugate: This Malondialdehyde antibody is conjugated to Atto 390

Application: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (IHC)

Specificity: Specific for MDA conjugated proteins. Does not detect free MDA. Does not cross-react with Acrolein, Crotonaldehyde, Hexanoyl Lysine, 4-HHE, 4-HNE, or Methylglyoxal modified proteins.

Purification: Protein G Purified

Immunogen: Synthetic Malondialdehyde modified Keyhole Limpet Hemocyanin (KLH).

Clone: 11E3

Isotype: IgG1

Application Details

Application Notes:

• WB (1:1000)
• ICC/IF (1:50)
• ELISA (1:1000)
• optimal dilutions for assays should be determined by the user.

Comment:

A 1:1000 dilution of ABIN5067362 was sufficient for detection of Malondialdehyde in 2 μg of Malondialdehyde conjugated to BSA by ECL immunoblot analysis using Goat Anti-Mouse IgG:HRP as the secondary Antibody.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS pH 7.4, 50 % glycerol, 0.09 % Sodium azide, Storage buffer may change when conjugated

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Conjugated antibodies should be stored at 4°C

Target Details for Malondialdehyde

Target: Malondialdehyde (MDA)

Alternative Name: Malondialdehyde (MDA Products)

Target Type: Chemical

Background: Malondialdehyde (MDA) is the biomarker in greatest diagnostic use, due to its molecular stability. This three-carbon, low-molecular weight aldehyde has a strong affinity for amino acids, which results in adduct formation to both free amino acids and proteins. Increased MDA levels have been found at correlating levels in breast cancer, and lung cancer patients. Other diseased states with elevated MDA levels include diabetes and Alzheimer's disease. Multiple laboratory techniques exist for quantification of MDA levels, including the thiobarbituric acid reactive substances (TBARS) assay. In addition to use as a biomarker, MDA has been shown to have mutagenic effects on tissues themselves as adduct formation can result in DNA cross-linking.